The purpose of this study is to assess the effectiveness of daratumumab SC in treating patients with ... first within 10 to 14 days prior to dosing and the second within 24 hours prior to dosing; A ...

Dose escalation of KY-0118, PD-1, and IL-2v due-target fusion protein in patients with advanced renal clear cell carcinoma, urothelial carcinoma, and malignant melanoma. This is an ASCO Meeting ...

Shares of Prothena PRTA tumbled 22.5% in after-hours trading on May 23 after it announced the discontinuation of the ...

It’s currently in first place in the free games category for both iPhone and iPad, less than a day after returning to the US App Store. No surprise after an almost five-year absence. A weekly ...

in favor of the benefit-risk profile of single-agent DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) for the treatment of adult patients with high-risk smoldering multiple myeloma (HR-SMM).

Eleven patients discontinued daratumumab treatment due to TEAEs, whereas 90 patients underwent dose modifications as a result; however, there were no differences in efficacy observed in patients with ...

cDivision of Endocrinology, Metabolism & Lipid Research, Washington University School of Medicine, St Louis, MO, USA dDivision of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD ...

How cancer patients feel physically before beginning treatment with daratumumab can predict how long they will live and how well they will respond to this multiple myeloma therapy, according to ...

and monoclonal antibodies like daratumumab. Regimens like VCD and Dara-VTD are common, particularly among transplant-eligible patients. While early response rates are often strong, relapse remains ...